{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:04Z","timestamp":1793119624444,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.rmed.2025.108520","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:11:14Z","timestamp":1763637074000},"page":"108520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Predictive value of Eastern Cooperative Oncology Group performance status and body mass index for antifibrotic tolerability and prognosis in patients with idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7520-3133","authenticated-orcid":false,"given":"Hirotoki","family":"Tsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-9526","authenticated-orcid":false,"given":"Ryosuke","family":"Tanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-1296","authenticated-orcid":false,"given":"Tamio","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2025.108520_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108520_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108520_bib3","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02279-2019","article-title":"Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: Long-term results of the INSIGHTS-IPF registry","volume":"56","author":"Behr","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108520_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.resinv.2014.08.003","article-title":"The usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment","volume":"53","author":"Homma","year":"2015","journal-title":"Respirat. Investig."},{"key":"10.1016\/j.rmed.2025.108520_bib8","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/resp.13138","article-title":"Disease severity staging system for idiopathic pulmonary fibrosis in Japan","volume":"22","author":"Kondoh","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2025.108520_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.resinv.2016.02.009","article-title":"Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis","volume":"54","author":"Kondoh","year":"2016","journal-title":"Respirat. Investig."},{"key":"10.1016\/j.rmed.2025.108520_bib10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1378\/chest.14-0453","article-title":"Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis","volume":"147","author":"Kim","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.108520_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/jcm12020498","article-title":"A systematic review of the prognostic significance of the body mass index in idiopathic pulmonary fibrosis","volume":"12","author":"Zinellu","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.rmed.2025.108520_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2311845","article-title":"Body mass index and weight loss as risk factors for poor outcomes in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"56","author":"He","year":"2024","journal-title":"Ann. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12325-022-02411-y","article-title":"Real-world safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: interim report of a post-marketing surveillance in Japan","volume":"40","author":"Ogura","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.rmed.2025.108520_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.resinv.2020.08.003","article-title":"Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis","volume":"59","author":"Uchida","year":"2021","journal-title":"Respirat. Investig."},{"key":"10.1016\/j.rmed.2025.108520_bib15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.rmed.2025.108520_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619872890","article-title":"Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study","volume":"13","author":"Oishi","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.rmed.2025.108520_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DDDT.S284819","article-title":"Clinical significance of continuable treatment with nintedanib over 12 months for idiopathic pulmonary fibrosis in a real-world setting","volume":"15","author":"Kato","year":"2021","journal-title":"DDDT"},{"key":"10.1016\/j.rmed.2025.108520_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12890-023-02565-7","article-title":"Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment","volume":"23","author":"Herberts","year":"2023","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12931-022-01938-6","article-title":"Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis","volume":"23","author":"Kondoh","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108520_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.resinv.2023.04.007","article-title":"Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions","volume":"61","author":"Cilli","year":"2023","journal-title":"Respirat. Investig."},{"key":"10.1016\/j.rmed.2025.108520_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262795","article-title":"Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: a single-center retrospective study","volume":"17","author":"Komatsu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2025.108520_bib22","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.3390\/jcm12103564","article-title":"A real-world prognosis in idiopathic pulmonary fibrosis: a special reference to the role of antifibrotic agents for the elderly","volume":"12","author":"Honda","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.rmed.2025.108520_bib23","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108520_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmpb.2019.05.023","article-title":"Evaluate cutpoints: adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator","volume":"177","author":"Og\u0142uszka","year":"2019","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.rmed.2025.108520_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98161-y","article-title":"Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis","volume":"11","author":"Suzuki","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2025.108520_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","article-title":"Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences","volume":"190","author":"Natsuizaka","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108520_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/resp.13943","article-title":"Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy","volume":"26","author":"Suzuki","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2025.108520_bib28","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3390\/cancers12051187","article-title":"The relationship between ECOG-PS, mGPS, BMI\/WL grade and body composition and physical function in patients with advanced cancer","volume":"12","author":"Dolan","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.rmed.2025.108520_bib29","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/s41598-020-59100-5","article-title":"Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis","volume":"10","author":"Nakano","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2025.108520_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume","volume":"72","author":"Kolb","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2025.108520_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/13993003.01966-2015","article-title":"Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function","volume":"48","author":"Albera","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108520_bib32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12890-021-01595-3","article-title":"Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis","volume":"21","author":"Sugino","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12890-017-0468-5","article-title":"Unmet needs in the treatment of idiopathic pulmonary fibrosis\u2013insights from patient chart review in five European countries","volume":"17","author":"Maher","year":"2017","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0053-2017","article-title":"When to start and when to stop antifibrotic therapies","volume":"26","author":"Torrisi","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2025.108520_bib35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.resinv.2024.09.008","article-title":"Factors associated with non-intervention of antifibrotic agents in IPF patients","volume":"62","author":"Asami-Noyama","year":"2024","journal-title":"Respirat. Investig."},{"key":"10.1016\/j.rmed.2025.108520_bib36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.chest.2023.11.035","article-title":"Comparison of pirfenidone and nintedanib: post hoc analysis of the CleanUP-IPF study","volume":"165","author":"Kim","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.108520_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305429","article-title":"Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis","volume":"19","author":"Sugino","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2025.108520_bib38","article-title":"Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2025.108520_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12931-019-1093-z","article-title":"Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21","volume":"20","author":"Jin","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108520_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel mechanisms for the antifibrotic action of nintedanib","volume":"54","author":"Rangarajan","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2025.108520_bib41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.21037\/jtd-23-1057","article-title":"Pirfenidone and nintedanib attenuate pulmonary fibrosis in mice by inhibiting the expression of JAK2","volume":"16","author":"Yang","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.rmed.2025.108520_bib42","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.3390\/ijms19113611","article-title":"The role of TGF-\u03b2 signaling in lung cancer associated with idiopathic pulmonary fibrosis","volume":"19","author":"Saito","year":"2018","journal-title":"IJMS"},{"key":"10.1016\/j.rmed.2025.108520_bib43","article-title":"Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study, Pulmonary","volume":"64","author":"Landi","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2025.108520_bib44","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/jcmm.17673","article-title":"Pirfenidone suppressed triple\u2010negative breast cancer metastasis by inhibiting the activity of the TGF-\u03b2\/SMAD pathway","volume":"27","author":"Luo","year":"2023","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib45","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.rmed.2025.108520_bib46","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.rmed.2025.108520_bib47","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jcsm.12441","article-title":"Tumour\u2010derived transforming growth factor\u2010\u03b2 signalling contributes to fibrosis in patients with cancer cachexia","volume":"10","author":"Lima","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.rmed.2025.108520_bib48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1183\/09031936.00077309","article-title":"Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology","volume":"35","author":"Vancheri","year":"2010","journal-title":"Eur. Respir. J."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:34:04Z","timestamp":1773261244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125005839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"alternative-id":["S0954611125005839"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108520","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of Eastern Cooperative Oncology Group performance status and body mass index for antifibrotic tolerability and prognosis in patients with idiopathic pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108520"}}